
Blue Carbon: A Water Body as a Carbon and ESG Asset
What blue carbon is, how water bodies store carbon and what an ESG report gives. AVELIFE roadmap: pilot, measurement, methodology.
Most antiviral drugs are developed against a specific virus or a narrow group of related pathogens. That makes sense: viruses differ greatly in structure, genome and the way they enter a cell. During a new epidemic, however, narrow specificity means the search often has to start almost from scratch. That is why science looks for broad-spectrum drugs: molecules able to act on at least several species or families of viruses through a shared vulnerability.
“Broad spectrum” does not mean “against all viruses”. It is a working concept that needs a precise definition: activity in cell culture, protection in an animal model and proven clinical benefit are different levels of evidence. A careful review should state both the range of activity and the model in which it was obtained.
For many RNA viruses, the key target is RNA-dependent RNA polymerase, the enzyme that copies the viral genome. The sequences differ, but the catalytic elements are often conserved, because replication is impossible without them. Nucleoside analogues can mimic the building blocks of RNA and disrupt copying. At the same time, each molecule has its own spectrum, its own way of being activated in the cell, its own pharmacokinetics and safety profile.
Similar logic applies to proteases, helicases and other enzymes without which a virus cannot complete its life cycle. In 2026, researchers described a computational pipeline that combines structure prediction, sequence alignment and a search for accessible conserved pockets. On alphavirus proteins, the method identified potential sites for future direct inhibitors. This is target identification, not proof of a finished drug; details are in the original Antiviral Research paper.

| Approach | Potential advantage | Key limitation | What is measured |
|---|---|---|---|
| Direct action on the virus | Higher specificity for a viral enzyme | The target may differ between families; resistance mutations are possible | Enzyme inhibition, replication and the emergence of resistant variants |
| Action on a host cell factor | Different viruses may use the same cellular process; higher barrier to resistance | Risk of affecting normal cell function | Antiviral effect, cell viability, therapeutic window |
| Activation of the innate response | Potentially covers different RNA and DNA viruses | Excessive or mistimed immune activation can cause harm | Response markers, viral load, inflammation and safety |
A review in the Journal of Clinical Investigation organizes direct and host-targeted strategies and explains why shared cellular mechanisms are attractive for a broad spectrum. The authors also caution that activity across different viral models still has to be weighed against toxicity and the real therapeutic window. Open-access version: Preparing for the next viral threat with broad-spectrum antivirals.
The nucleoside analogue 4′-fluorouridine suppressed a number of enteroviruses in cell models, including various Coxsackie viruses and enterovirus D68. The authors linked the effect to interaction with the viral 3D polymerase and disruption of RNA synthesis. But the study remains preclinical: a broad effect within the enterovirus group is not the same as a clinically proven treatment for humans. Source: the original 4′-fluorouridine publication.
Another example is GHP-88309, a non-nucleoside allosteric inhibitor of paramyxovirus polymerase. The study showed activity against several members of the family and an effect in an animal model after oral administration. At the same time, the spectrum was limited to related paramyxoviruses, and a long road to clinical evaluation remained. Details: the original study in Science Translational Medicine.

In an outbreak, what matters is not only an individual candidate but also ready infrastructure: target structures, validated assays, series of chemical leads and synthesis data. This is exactly the logic applied by the NIH AViDD centers. According to the official description, nine centers work on SARS-CoV-2 and on virus families with pandemic potential, including filoviruses, flaviviruses, picornaviruses and togaviruses. This is a portfolio approach, not a promise of a universal pill. Source: NIH on the creation of AViDD.
Within ASAP AViDD, more than 140 researchers developed drugforge, an open pipeline for structure- and ligand-based screening. The publication describes standardized computational steps and a test application to high-risk virus families. The advantage of such a platform is reproducibility and reuse of tools; the limitation is that a computational ranking still requires synthesis and experiment. See the original description of the structure-based pipeline.
Even a conserved enzyme can differ in pocket shape, reaction rate and accessibility in the infected cell. Prodrugs are activated by cellular enzymes unevenly in different tissues. One virus may replicate mainly in the respiratory tract, another in the liver or the nervous system, so exposure in different organs is needed. Interactions with human polymerases and mitochondria are assessed separately.
For host-targeted agents, the main trade-off is breadth versus safety. A cellular factor may be needed by many viruses, but it belongs to the organism. That is why it is important to demonstrate a therapeutic window: the concentration at which replication is suppressed while normal cell function is preserved. A result in a continuous laboratory cell line must be confirmed in primary cells, organoids, animal models and, ultimately, in the clinic.
For an honest assessment, one needs to see a “compound – virus – model” matrix. Useful indicators include half-maximal effective concentration, cytotoxicity, selectivity index, reproducibility across several cell systems, reduction of viral load in vivo, pharmacokinetics and the barrier to resistance. The label “broad spectrum” is convincing only when activity is demonstrated under comparable protocols, not pieced together from incompatible one-off reports.
It is also important to define the desired spectrum in advance. A candidate against several coronaviruses, against one large family of RNA viruses and against both RNA and DNA viruses are three different goals with different risk. A realistic step is often a pan-family drug aimed at one family but ready for rapid adaptation to a new member of it.
The search for a broad spectrum is a preparedness strategy, not a shortcut to universal medicines. The most promising directions combine conserved viral enzymes, carefully chosen host factors and platforms able to quickly test candidates against new isolates. Every widening of the spectrum must be accompanied by equally thorough checks of safety, tissue exposure and resistance.
No. Viruses are too diverse. Even a broad-spectrum agent has defined limits of activity and indications.
They are essential for copying the genome, and the catalytic elements are often conserved. Even so, structural differences, activation of the molecule and pharmacokinetics still limit the spectrum.
In theory the barrier may be higher, because the cellular target is not encoded by the virus. But a virus can alter the interactions, and an effect on cell function creates separate safety risks.
The molecule suppresses the virus in a laboratory cell system under certain conditions. This is a necessary early signal, but it does not prove efficacy or safety in humans.

What blue carbon is, how water bodies store carbon and what an ESG report gives. AVELIFE roadmap: pilot, measurement, methodology.

How silica sorption, biochar and bacterial strains purify water: sorbent, biosurfactant, sediment back to soil. AVELIFE bioactivator technology.

AVELIFE water body restoration complex: survey, water treatment, sediment work and an ESG report. Kyiv, 2025. Request a pilot.